JITC

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
Paul B Chapman, Vetri Sudar Jayaprakasam, Katherine S Panageas, Margaret Callahan, Michael A Postow, Alexander N Shoushtari, Jedd D Wolchok, Allison Betof Warner

Journal for ImmunoTherapy of Cancer Oct 2021, 9 (10) e003395; DOI: 10.1136/jitc-2021-003395
Distinct mutational profile and immune microenvironment in microsatellite-unstable and POLE-mutated tumors
Hee Sang Hwang, Deokhoon Kim, Jene Choi

Journal for ImmunoTherapy of Cancer Oct 2021, 9 (10) e002797; DOI: 10.1136/jitc-2021-002797
Helicobacter pylori infection disturbs the tumor immune microenvironment and is associated with a discrepant prognosis in gastric de novo diffuse large B-cell lymphoma
Yuwei Deng, Wenjia Su, Junwen Zhu, Hongfei Ji, Xiaoping Zhou, Jingshu Geng, Jiayu Zhu, Qingyuan Zhang

Journal for ImmunoTherapy of Cancer Oct 2021, 9 (10) e002947; DOI: 10.1136/jitc-2021-002947
4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells
Emiliano Roselli, Justin C Boucher, Gongbo Li, Hiroshi Kotani, Kristen Spitler, Kayla Reid, Estelle V Cervantes, Yannick Bulliard, Nhan Tu, Sae Bom Lee, Bin Yu, Frederick L Locke, Marco L Davila

Journal for ImmunoTherapy of Cancer Oct 2021, 9 (10) e003354; DOI: 10.1136/jitc-2021-003354
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
Anders Handrup Kverneland, Christopher Aled Chamberlain, Troels Holz Borch, Morten Nielsen, Sofie Kirial Mørk, Julie Westerlin Kjeldsen, Cathrine Lund Lorentzen, Lise Pyndt Jørgensen, Lene Buhl Riis, Christina Westmose Yde, Özcan Met, Marco Donia, Inge Marie Svane

Journal for ImmunoTherapy of Cancer Oct 2021, 9 (10) e003499; DOI: 10.1136/jitc-2021-003499
Immunological configuration of ovarian carcinoma: features and impact on disease outcome
Jitka Fucikova, An Coosemans, Sandra Orsulic, David Cibula, Ignace Vergote, Lorenzo Galluzzi, Radek Spisek

Journal for ImmunoTherapy of Cancer Oct 2021, 9 (10) e002873; DOI: 10.1136/jitc-2021-002873
Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer
Patricia Rich, R Brian Mitchell, Eric Schaefer, Paul R Walker, John W Dubay, Jason Boyd, David Oubre, Ray Page, Mazen Khalil, Suman Sinha, Scott Boniol, Hafez Halawani, Edgardo S Santos, Warren Brenner, James M Orsini, Emily Pauli, Jonathan Goldberg, Andrea Veatch, Mitchell Haut, Bassam Ghabach, Savita Bidyasar, Maria Quejada, Waseemullah Khan, Kan Huang, Linda Traylor, Wallace Akerley

Journal for ImmunoTherapy of Cancer Oct 2021, 9 (10) e002989; DOI: 10.1136/jitc-2021-002989
Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach
Samuel Peter Heilbroner, Reed Few, Tomas G Neilan, Judith Mueller, Jitesh Chalwa, Francois Charest, Somasekhar Suryadevara, Christine Kratt, Andres Gomez-Caminero, Brian Dreyfus

Journal for ImmunoTherapy of Cancer Oct 2021, 9 (10) e002545; DOI: 10.1136/jitc-2021-002545
Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors
Chia-Ing Jan, Shi-Wei Huang, Peter Canoll, Jeffrey N Bruce, Yu-Chuan Lin, Chih-Ming Pan, Hsin-Man Lu, Shao-Chih Chiu, Der-Yang Cho

Journal for ImmunoTherapy of Cancer Oct 2021, 9 (10) e003050; DOI: 10.1136/jitc-2021-003050
JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
Yosuke Miyamoto, Toshiyuki Kozuki, Keisuke Aoe, Sae Wada, Daijiro Harada, Michihiro Yoshida, Jun Sakurai, Katsuyuki Hotta, Nobukazu Fujimoto

Journal for ImmunoTherapy of Cancer Oct 2021, 9 (10) e003288; DOI: 10.1136/jitc-2021-003288

Main menu

JITC

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

JITC

Pages